HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ACAD

Acadia Pharmaceuticals Inc

Last Close
Dec 13 • 04:00PM ET
17.26
Dollar change
0.00
Percentage change
0.00 		%
Healthcare • Biotechnology • USA • NASD
Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN
 | Held by: IWM VTI XBI VB FBT VXF VBK IBB IWO SCHA
Scroll to Statements
IndexRUT P/E22.34 EPS (ttm)0.77 Insider Own1.26% Shs Outstand166.35M Perf Week-0.12%
Market Cap2.87B Forward P/E22.63 EPS next Y0.76 Insider Trans-3.48% Shs Float164.30M Perf Month-1.88%
Income128.51M PEG- EPS next Q0.23 Inst Own93.77% Short Float6.03% Perf Quarter6.94%
Sales929.24M P/S3.09 EPS this Y296.71% Inst Trans-4.75% Short Ratio6.94 Perf Half Y15.76%
Book/sh3.47 P/B4.97 EPS next Y4.80% ROA15.97% Short Interest9.91M Perf Year-39.37%
Cash/sh3.40 P/C5.08 EPS next 5Y- ROE27.36% 52W Range14.15 - 32.59 Perf YTD-44.87%
Dividend Est.- P/FCF14.17 EPS past 5Y28.03% ROI20.81% 52W High-47.04% Beta0.40
Dividend TTM- Quick Ratio2.11 Sales past 5Y27.73% Gross Margin91.61% 52W Low21.98% ATR (14)0.73
Dividend Ex-Date- Current Ratio2.29 EPS Y/Y TTM185.18% Oper. Margin12.08% RSI (14)53.74 Volatility5.73% 4.23%
Employees598 Debt/Eq0.09 Sales Y/Y TTM47.06% Profit Margin13.83% Recom1.85 Target Price25.11
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q149.70% Payout- Rel Volume1.37 Prev Close17.26
Sales Surprise0.63% EPS Surprise44.82% Sales Q/Q18.28% EarningsNov 06 AMC Avg Volume1.43M Price17.26
SMA202.10% SMA508.01% SMA2003.48% Trades Volume1,958,003 Change0.00%
Date Action Analyst Rating Change Price Target Change
Oct-10-24Resumed Raymond James Mkt Perform
Aug-07-24Downgrade Morgan Stanley Overweight → Equal-Weight $28 → $20
Jun-27-24Initiated BMO Capital Markets Outperform $31
Mar-12-24Reiterated Needham Buy $36 → $32
Mar-12-24Downgrade Mizuho Buy → Neutral $39 → $25
Jan-30-24Initiated Robert W. Baird Outperform $40
Jan-24-24Upgrade Needham Hold → Buy $37
Dec-19-23Upgrade Morgan Stanley Equal-Weight → Overweight $31 → $40
Dec-14-23Downgrade Deutsche Bank Buy → Hold $25
Dec-13-23Initiated Citigroup Buy $38
Show Previous Ratings
Dec-11-24 04:05PM
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
(Business Wire)
Dec-09-24 09:00AM
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
(Business Wire) +8.56%
Dec-03-24 09:50AM
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
(Zacks)
08:32AM
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
(Zacks)
Nov-27-24 07:06AM
Acadia signs agreement with Saniona to commercialise SAN711
(Pharmaceutical Technology)
04:05PM Loading…
Nov-26-24 04:05PM
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
(Business Wire)
Nov-21-24 04:05PM
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
(Business Wire)
Nov-15-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Nov-12-24 09:50AM
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
(Zacks)
Nov-07-24 06:00AM
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
(GuruFocus.com) +8.93%
Nov-06-24 05:15PM
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
(Zacks) +5.27%
04:13PM
Acadia: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
(Business Wire)
Nov-05-24 04:05PM
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
(Business Wire)
Oct-31-24 02:22PM
ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024
(Insider Monkey)
06:41PM Loading…
Oct-17-24 06:41PM
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
(Business Wire)
07:28AM
Health Canada approves Acadias DAYBUE for Rett syndrome
(Pharmaceutical Technology)
Oct-16-24 04:07PM
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome
(Business Wire)
Oct-08-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-26-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-23-24 04:15PM
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
(Business Wire)
Aug-29-24 08:30AM
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
(Zacks)
Aug-28-24 04:05PM
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
(Business Wire)
Aug-14-24 08:04AM
Ryan Reynolds Announces More to Parkinsons Campaign
(Business Wire)
Aug-07-24 04:30PM
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
(Business Wire) -19.52%
04:14PM
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
(Investor's Business Daily)
08:16AM
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
(Zacks)
Aug-06-24 05:45PM
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
(Zacks)
04:42PM
Acadia: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
(Business Wire)
10:01AM Loading…
Jul-30-24 10:01AM
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
(Zacks)
Jul-24-24 04:05PM
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
(Business Wire)
Jul-18-24 09:04AM
Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating Long-Term Safety and Efficacy of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med
(Business Wire)
Jul-16-24 10:28AM
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
(Zacks)
Jun-21-24 12:24PM
Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?
(Insider Monkey)
10:53AM
7 Best Halal Stocks To Buy Now (Debt Free)
(Insider Monkey)
Jun-18-24 09:04AM
Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
(Business Wire)
Jun-07-24 11:30AM
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
(Zacks)
May-29-24 10:01AM
3 Sorry Pharma Stocks to Sell in May While You Still Can
(InvestorPlace)
May-17-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
May-15-24 09:05AM
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
(Business Wire)
May-10-24 01:15PM
ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
(GuruFocus.com)
11:20AM
UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating
(MT Newswires)
10:01AM
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
(MT Newswires)
May-09-24 04:58PM
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
(Business Wire) -11.21%
03:29PM
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
(Insider Monkey)
11:07AM
Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating
(MT Newswires)
05:59AM
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
(Zacks)
03:37AM
ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...
(GuruFocus.com)
May-08-24 08:57PM
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
(InvestorPlace)
05:15PM
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
(Zacks)
04:15PM
Acadia: Q1 Earnings Snapshot
(Associated Press Finance)
04:05PM
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
(Business Wire)
May-04-24 02:27AM
Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)
(GuruFocus.com)
May-01-24 10:01AM
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
(Zacks)
Apr-30-24 12:17PM
UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating
(MT Newswires)
Apr-29-24 04:16PM
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
(Business Wire)
Apr-24-24 04:05PM
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
(Business Wire)
Apr-22-24 09:04AM
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
(Business Wire)
Apr-20-24 09:15AM
5 Best Healthcare Stocks to Buy Under $20
(Insider Monkey)
Apr-19-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Apr-17-24 04:05PM
Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
(Business Wire)
Apr-11-24 02:10PM
3 Pharma Stocks to Sell in April Before They Crash & Burn
(InvestorPlace)
Apr-10-24 01:28AM
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
(GuruFocus.com)
Apr-02-24 04:05PM
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
(Business Wire)
Apr-01-24 04:05PM
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
(Business Wire)
Mar-28-24 11:30AM
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
(Zacks)
02:00AM
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
(GuruFocus.com)
Mar-20-24 01:31PM
Billionaire Steve Cohen and Insiders are Buying These 5 Stocks
(Insider Monkey)
Mar-15-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Mar-14-24 06:49PM
3 Pharma Stocks to Sell in March Before They Crash & Burn
(InvestorPlace)
Mar-13-24 04:05PM
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
(Business Wire)
Mar-12-24 04:08PM
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
(Investor's Business Daily) -17.20%
03:05PM
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
(Investopedia)
11:06AM
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
(Zacks)
09:30AM
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
(InvestorPlace)
07:43AM
5 Things to Know Before the Stock Market Opens
(Investopedia)
Mar-11-24 04:46PM
UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
(Reuters)
04:13PM
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
(Reuters)
04:05PM
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
(Business Wire)
Feb-29-24 09:05AM
Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024
(Business Wire)
08:44AM
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-28-24 04:05PM
Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch
(Investor's Business Daily) -9.92%
09:12AM
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
(Zacks)
Feb-27-24 05:20PM
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
(Zacks)
04:56PM
ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023
(GuruFocus.com)
04:27PM
Acadia: Q4 Earnings Snapshot
(Associated Press Finance)
04:05PM
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
(Business Wire)
Feb-22-24 08:16PM
ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
(GlobeNewswire)
Feb-21-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Feb-20-24 10:00AM
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
(Zacks)
Feb-13-24 04:05PM
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
(Business Wire)
Feb-08-24 01:15PM
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
(InvestorPlace)
Jan-30-24 08:48PM
Acadia Announces Additions to Executive Team
(Business Wire)
05:00PM
20 Countries With The Highest Number of Drug Trafficking in the World
(Insider Monkey)
Jan-26-24 05:31PM
Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US
(Insider Monkey)
Jan-25-24 08:42AM
10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts
(Insider Monkey)
Jan-19-24 04:05PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jan-18-24 04:05PM
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
(Business Wire)
Jan-12-24 05:02PM
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares
(GuruFocus.com)
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Teehan BrendanEVP, COO, HEAD OF COMMERCIALNov 19 '24Sale16.8110,329173,63062,105Nov 19 08:43 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERNov 19 '24Sale16.814,07368,46719,863Nov 19 08:41 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERNov 19 '24Sale16.8110,259172,45453,302Nov 19 08:40 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 19 '24Sale15.289,733148,72043,735Aug 20 06:46 PM
Teehan BrendanEVP, COO, HEAD OF COMMERCIALAug 19 '24Sale15.289,534145,68052,177Aug 20 06:43 PM
DAVIS STEPHENCEOAug 19 '24Sale15.2831,747485,094186,555Aug 20 06:40 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERJun 10 '24Sale14.7997514,42034,564Jun 11 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMay 02 '24Sale16.943,50359,34132,053May 03 06:00 PM
Teehan BrendanEVP, COO, HEAD OF COMMERCIALMay 02 '24Sale16.943,47758,90042,133May 03 06:00 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 02 '24Sale16.941,32622,46214,370May 03 06:00 PM
DAVIS STEPHENCEOMay 02 '24Sale16.9411,427193,573155,231May 03 06:00 PM
DAVIS STEPHENCEOApr 08 '24Sale17.8726,574474,877144,267Apr 09 06:00 PM
Teehan BrendanEVP, COO, HEAD OF COMMERCIALApr 08 '24Sale17.872,56845,89038,796Apr 09 06:00 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERApr 08 '24Sale17.871,79031,98713,100Apr 09 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERApr 08 '24Sale17.872,71648,53528,742Apr 09 06:00 PM
Teehan BrendanEVP, COO, HEAD OF COMMERCIALMar 27 '24Sale17.905,14092,00636,340Mar 27 08:00 PM
DAVIS STEPHENCEOMar 27 '24Sale17.9017,714317,081118,842Mar 27 07:58 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMar 27 '24Sale17.905,43497,26926,183Mar 27 07:57 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERFeb 26 '24Sale24.6777219,04521,067Feb 27 06:13 PM
Teehan BrendanEVP, COO, HEAD OF COMMERCIALFeb 26 '24Sale24.6762415,39431,432Feb 27 06:10 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERFeb 26 '24Sale24.6747411,69411,391Feb 27 06:07 PM
DAVIS STEPHENCEOFeb 26 '24Sale24.675,577137,585101,890Feb 27 06:02 PM
DAVIS STEPHENCEOJan 08 '24Sale29.963,732111,81196,521Jan 09 06:00 PM
Teehan BrendanEVP, COO, Head of CommercialJan 08 '24Sale29.9673121,90130,949Jan 09 06:00 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryJan 08 '24Sale29.9659017,67646,901Jan 09 06:00 PM
Kihara JamesPrincipal Accounting OfficerDec 15 '23Sale28.302,00056,60011,025Dec 15 07:37 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.